When to operate? ovarian cancer trial tests best time for surgery after chemo
NCT ID NCT03579394
First seen Jan 07, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients received standard carboplatin and paclitaxel chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Grenoble-Alpes - Site Nord (La Tronche)
Grenoble, 38043, France
-
CHU de BREST - Hôpital Cavale Blanche
Brest, 29200, France
-
CHU de Limoges - Hôpital de la Mère et de l'Enfant
Limoges, 87000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14000, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Universitaire Bretonneau
Tours, 37000, France
-
Centre Hospitalier Universitaire Caen
Caen, 14033, France
-
Centre Jean Bernard - Clinique Victor Hugo
Le Mans, 72000, France
-
Centre Jean Perrin
Clermont-Ferrand, 63000, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Clinique Médico-chirurgicale CHARCOT
Sainte-Foy-lès-Lyon, 69110, France
-
Groupe Hospitalier Pitié Salpétrière
Paris, 75651, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Privé du Confluent
Nantes, 44202, France
-
Hôpital René Huguenin, Institut Curie
Saint-Cloud, 92210, France
-
Hôpital Saint-Joseph
Marseille, 13008, France
-
Hôpital Simone Veil
Eaubonne, 95602, France
-
Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers
Poitiers, 86021, France
-
Hôpital du Scorff
Lorient, 56100, France
-
ICA - Polyclinique Urbain V
Avignon, 84000, France
-
ICM Val d'Aurelle
Montpellier, 34298, France
-
ICO Centre René Gauducheau
Saint-Herblain, 44805, France
-
Institut Bergonié
Bordeau, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Jean Godinot
Reims, 51056, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin and paclitaxel chemotherapy followed by interval debulking surgery
What this could lead to
If successful, this could help doctors decide the best timing for surgery after chemotherapy to improve how long patients stay free of ovarian cancer.
What could go wrong
This is a completed trial, but it only looked at timing of surgery, not a new drug. Results may not apply to all ovarian cancer types or stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.